Dexcel Pharma Technologies Form 3 Protalix BioTherapeutics / Dan Oren ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dexcel Pharma Technologies Ltd.

(Last)

(First)

(Middle)

10 HAKIDMA STREET

(Street)

YOKNEAM

2069200

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/12/2021

3. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,556,031	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Purchase Warrants	03/11/2020	03/11/2025	Common Stock	2,816,901⁽¹⁾	2.36	D

1. Name and Address of Reporting Person^*

Dexcel Pharma Technologies Ltd.

(Last)

(First)

(Middle)

10 HAKIDMA STREET

(Street)

YOKNEAM

2069200

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Oren Dan

(Last)

(First)

(Middle)

1 DEXCEL STREET

(Street)

OR AKIVA

3060000

(City)

(State)

(Zip)

Explanation of Responses:

1. The warrants contain a blocker that prohibits the holder from exercising the warrants if such exercise will result in beneficial ownership of more the 9.99% of the Issuer's outstanding common shares by the warrantholder and its affiliates. Since the reporting persons' beneficial ownership percentage is over 9.99%, the warrants are currently not exercisable.

	/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman	02/16/2021
	/s/ Dan Oren	02/16/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Dexcel Pharma Technologies Form 3Protalix BioTherapeutics / Dan Oren ownership change